Lux Biosciences, Inc.

Quick facts

Phase 3 pipeline

• LX211
  LX211 is an investigational therapeutic in phase 3 development by Lux Biosciences with an undisclosed mechanism of action.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Lux Biosciences, Inc. portfolio CI brief
• Lux Biosciences, Inc. pipeline updates RSS